|
 |
FabrazymeThis page contains recent news articles, when available, and an overview of Fabrazyme but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Today about 60% of all recombinant protein pharmaceuticals are produced in mammalian cells (Avastin, Advate, Erbitux, Rebif, Herceptin, Advate, Fabrazyme… PR Web (press release), Synageva BioPharma Appoints Sanj K. Patel President and Chief ... - Sep 4, 2008 Sanj also led the Fabrazyme(R) clinical operations team and development program to FDA approval in April 2003. Sanj Patel also held clinical research and MarketWatch Genzyme Beats, Holds to Lowered Guidance - Jul 23, 2008 However, sales of the company's lysosomal storage disorder drugs, Cerezyme, Fabrazyme and Myozyme all came in above expectations. Sales of Gaucher disease TheStreet.com Genzyme Reports Strong Second-Quarter Growth - Jul 23, 2008 Sales of Fabrazyme(R) (agalsidase beta) grew 21 percent, rising to $126.6 million from $104.3 million. Sales of Aldurazyme(R) (laronidase) increased 33 FOXBusiness Genzyme Corp. Q2 2008 Earnings Call Transcript - Jul 23, 2008 Fabrazyme increased to $127 million or 21% increase, with volume largely driven from increases in both the United States, as well as in Europe. Seeking Alpha, A Few Healthy Pockets - May 29, 2008 Two examples are Fabrazyme and Myozyme—both treat rare diseases that affect a small population of less than 100000 people but are thought to be the best On Wall Street, Genzyme Reports Strong First-Quarter Growth - 23 Apr 2008 Sales of Fabrazyme(R) (agalsidase beta) grew 16 percent in the quarter, rising to $116.5 million from $100.7 million in the first quarter last year. PR Newswire (press release), Genzyme Reports Strong First-Quarter Growth - 23 Apr 2008 Genzyme(R), Myozyme(R), Fabrazyme(R), Cerezyme(R), Thyrogen(R), Renagel(R), Renvela(R), Thymoglobulin(R), Synvisc(R), Campath(R) and Clolar(R) are CNNMoney.com (press release) EARNINGS PREVIEW: Biotechs' 1Q Should See Price, Forex Gains - Apr 8, 2008 Key Issues: Unlike most drug makers, Genzyme focuses on treating rare conditions and its lead therapeutic group - Cerezyme, Fabrazyme, Myozyme and CNNMoney.com Genzyme Corp swings into the black for fourth quarter - Feb 14, 2008 Genzyme Corp has posted a strong set of results for the fourth quarter of 2007, with growth being driven once again by Cerezyme, Fabrazyme and Renagel. Pharma Times (subscription), Genzyme Delivers Strong Fourth Quarter to Conclude Outstanding Year - Feb 14, 2008 Sales of Fabrazyme® (agalsidase beta) are expected to reach $495-$505 million this year, compared with $424 million in 2007. The European Commission has Lifescience-online, Genzyme Meets Views, Sees Strong Revenue - Feb 13, 2008 Fabry disease treatment Fabrazyme and Pompe disease treatment Myozyme generated sales of $114 million and $62 million, respectively. TheStreet.com Genzyme Turns To Profit In Q4 On Strong Drug Sales; Guides Q1 ... - Feb 13, 2008 Sales of the company's Fabry disease treatment Fabrazyme increased 18% to $114 million from $97 million in the same quarter last year. For Fiscal year 2007, RTT News, Genzyme Delivers Strong Fourth Quarter to Conclude Outstanding Year - Feb 13, 2008 GENZYME 2008 GUIDANCE 2008 Guidance DESCRIPTION Ranges Renagel / Renvela $690 $700 Total Renal 800 815 Cerezyme 1215 1240 Fabrazyme 495 505 Myozyme 320 330 PR Newswire (press release), Genzyme Reports 21 Percent Increase in Fourth-Quarter Revenue - Jan 8, 2008 Fourth-quarter sales of Fabrazyme(R) (agalsidase beta) were $114 million, up 18 percent from $97 million in the same quarter a year ago. FOX News Genzyme Corporation Updated Company Profile : Outlook, Strategy ... - Jan 8, 2008 2001-06 39 Product analysis, 2001-06 39 Growth drivers 39 Cerezyme 39 Fabrazyme 40 Renagel 40 Synvisc 40 Operating revenue and cost analysis, Reuters Ahead of the Bell: Genzyme - Jan 9, 2008 Several analysts said sales of the company's biggest drugs, including Cerezyme, Myozyme and Fabrazyme, surpassed their estimates. CNNMoney.com Genzyme 'bullish' on future growth - Jan 8, 2008 Fabrazyme, a treatment for Fabry disease, increased 18 percent to $114 million. Genzyme's drugs for rare hereditary disorders treat illnesses caused by a Boston Globe, UPDATE 2-Genzyme quarterly revenue slightly beats forecast - Jan 8, 2008 Sales of Fabrazyme, a treatment for Fabry disease, rose 18 percent to $114 million. Quarterly sales of Aldurazyme, an enzyme replacement therapy for a Reuters Genzyme Q4 Revenue Up 21 - Jan 8, 2008 The company said fourth quarter sales of its Fabry disease treatment Fabrazyme increased 18% to $114 million from $97 million in the same quarter last year. RTT News, Genzyme: following the RNA therapy trend - Jan 12, 2008 Increasing sales of the company's enzyme replacement therapies, Cerezyme (imiglucerase) for Gaucher disease; Genzyme's biggest selling product, Fabrazyme Pharmaceutical Business Review Me and my IV - Jan 8, 2008 The nurse, Toni, brought in the IV bag full of the lemonade-like liquid - Fabrazyme - that was soon to enter my bloodstream. A second later, my inexperience Morris Daily Herald, Biotech Company Specializes In Treatments For Rare Disorders - Jan 23, 2008 Genzyme also makes Fabrazyme, which generated $114 million in sales last quarter, up 18%, and $424 million for the year. The drug helps treat Fabry's CNNMoney.com Genzyme Provides Bullish Guidance - Jan 8, 2008 Coming in at the top end of estimates, Fabry disease treatment Fabrazyme and Pompe disease treatment Myozyme generated sales of $114 million and $62 million TheStreet.com High-profit products old and new keep Genzyme on the up - Jan 9, 2008 The more-established Cerezyme (imiglucerase), for Gaucher disease, was up 15% to $301 million, while fourth-quarter sales of Fabry disease therapy Fabrazyme Pharma Times (subscription), Isis and Genzyme sign $1.9 billion cholesterol alliance - Jan 8, 2008 ...such as the Gaucher disease treatment Cerezyme (imiglucerase), and Fabry disease drug Fabrazyme (agalsidase beta), that makes it an attractive partner Pharma Times (subscription), Genzyme Delivers Earnings Beat - Oct 24, 2007 Sales of Myozyme for Pompe disease rose to $53.6 million from $20.4 million in the same period a year ago; sales of Fabrazyme Fabry disease increased 12% TheStreet.com Earnings Preview: Genzyme - Oct 23, 2007 OVERVIEW: In July, the company said its second-quarter profit rose on higher sales of its Fabrazyme enzyme replacement therapy, Gaucher disease treatment CNNMoney.com Genzyme confident of 20% earnings growth for next five years - Oct 25, 2007 Genzyme Corp has posted a strong set of results for the third quarter of 2006, with growth being driven once again by Cerezyme, Fabrazyme and Renagel. Pharma Times (subscription), Amicus, Shire Team on Rare Gene R&D - Nov 8, 2007 Genzyme also reported $53.6 million in sales form Myozyme therapy for Pompe disease and $104.6 million in sales of Fabrazyme, a recombinant form of a human TheStreet.com Genzyme Reports Strong Earnings Growth in Third Quarter - Oct 24, 2007 Sales of Fabrazyme(R) (agalsidase beta) increased 12 percent to $104.6 million, compared with $93.2 million in the same quarter last year. CNNMoney.com Profit soars tenfold at Genzyme Corp. - Oct 25, 2007 The medicines include Fabrazyme for Fabry disease and Aldurazyme for a genetic condition known as MPS1. Each drug costs an average $200000 a year per Boston Globe, Genzyme reports strong third-quarter earnings - Oct 24, 2007 Fabrazyme sales rose 12% to $105 million. Sales of its renal-failure product Renagel were up 14% to $154 million. Myozyme, its new therapy to treat Pompe MarketWatch UPDATE 1-Genzyme 3rd-quarter earnings beat expectations - Oct 24, 2007 Sales of Fabrazyme, for the treatment of the genetic disorder Fabry disease, rose 12 percent to $104.6 million, while sales of Cerezyme, for Gaucher disease Reuters Genzyme Profit Rises on Genetic-Disease Medicines (Update1) - Oct 24, 2007 Sales of Fabrazyme, for Fabry disease, climbed 12 percent to $104.6 million. Revenue from Myozyme, approved in April 2006, more than doubled to $53.6 Bloomberg LSD Deal Brings Amicus $50M Now, $390M Later - Nov 8, 2007 In the third quarter of 2007, Genzyme's Fabry disease drug Fabrazyme (agalsidase beta) brought in $104.6 million, while its Gaucher disease drug Cerezyme BioWorld Online, FOLD: Sees 52-Week High on Tuesday After Positive Ph I Study for ... - Oct 23, 2007 Genzyme, the early pioneer in this area, has developed Fabrazyme(R) (agalsidase beta) to replace the missing enzyme in patients with Fabry disease. Trading Markets (press release), Diseases without clout - Oct 9, 2007 Last year, the FDA approved one of Genzyme's orphan drugs: Fabrazyme, which can reverse kidney disease caused by Fabry disease, a metabolic genetic disorder Checkbiotech.org (press release), Genzyme Receives Approval to Market Elaprase(R) in Japan - Oct 4, 2007 The company also markets Cerezyme(R) (imiglucerase for injection) for Type 1 Gaucher disease; Fabrazyme(R) (agalsidase beta) for Fabry disease; CNNMoney.com Genzyme Begins Major Expansion of Boston Manufacturing Facility - Sep 18, 2007 Three are manufactured there: Cerezyme; Fabrazyme(R) (agalsidase beta) for Fabry disease; and Myozyme(R) (alglucosidase alfa) for Pompe disease. CNNMoney.com Genzyme to begin $150m expansion of Allston plant - Sep 14, 2007 It produces several drugs to treat rare diseases: Cerezyme for Gaucher disease, Fabrazyme for Fabry disease, and Myozyme for Pompe disease. Boston Globe, Genzyme expands flagship facility - Sep 18, 2007 Since then a further four products have been introduced to the facility including Fabrazyme (agalsidase beta) for Fabry disease, and Myozyme (alglucosidase US-PharmaTechnologist.com, Former teacher to stand trial on sex, drug charges - 07 Sep 2007 The treatments, Replagel and Fabrazyme, are the most expensive drug on the market, at $250000 to $300000 per patient per year. Some patients who had been ChronicleHerald.ca, Policy needed - Sep 5, 2007 Genzyme Canada makes fabrazyme for Fabry disease. I have Fabry disease, a rare genetic disorder as well as my daughter, grandson, and granddaughter. Mississauga News, Jumpstarting Genzyme - Jul 27, 2007 Motley FoolAll three of Genzyme's top products -- Cerezyme, Renagel, and Fabrazyme -- had double-digit percentage sales gains, and the company did a good job of Combination Therapy Halts Kidney Function Loss in Genetic Disease - Jul 26, 2007 MedPage Today,Adding agalsidase-β (Fabrazyme) to an ACE inhibitor and an angiotensin receptor blocker (ARB) produced a sustained reduction in proteinuria in six patients Genzyme says Q2 earnings up - Jul 25, 2007 Boston Business Journal,Genzyme said sales grew for many of its signature treatments including the enzyme replacement Fabrazyme, which reach more than $104 million in sales during Genzyme Boosts Second-Quarter Profit, Raises Forecast (Update2) - Jul 25, 2007 BloombergSales of Fabrazyme, which treats Fabry disease, rose 17 percent to $104.3 million. Medicines for rare ailments account for almost half of the Genzyme's Early intervention with (pr)Fabrazyme(R) key to preventing renal ... - Jun 15, 2007 PipelineReview.com (press release),The phase III extension study was undertaken to investigate the long-term safety and efficacy of Fabrazyme. Full approval was received from Health Canada Genzyme: Geared for Growth - Jun 11, 2007 BusinessWeekOther marketed ERT products include Fabrazyme, which was approved in the US and Europe for the treatment of Fabry disease, a rare genetic disorder. Genzyme's combination gene therapy shows potential for CNS disease - 25 May 2007 DrugResearcher.com,Gaucher disease, Fabrazyme (agalsidase beta) for Fabry disease, Aldurazyme (laronidase) for MPS I and Myozyme (alglucosidase alfa) for Pompe disease. Genzyme reports 57% profit spike - Apr 25, 2007 MarketWatchBOSTON (MarketWatch) -- Genzyme Corp. reported a 57% spike in first-quarter earnings early Wednesday, due largely to strong sales of such drugs as Fabrazyme Genzyme Reports Significant Revenue and Earnings Growth in First ... - Apr 25, 2007 MSN MoneyGenzyme's three other treatments for lysosomal storage disorders showed continued strength in the first quarter: Sales of Fabrazyme(R) (agalsidase beta) for Largest-ever Fabry study shows earlier treatment with (Pr ... - Jan 17, 2007 PipelineReview.com (press release),The study, entitled Agalsidase-Beta Therapy for Advanced Fabry Disease, has shown that early treatment with the enzyme replacement therapy Fabrazyme at 1 Genzyme Reports Strong Fourth-Quarter Revenue Growth to Conclude ... - Jan 10, 2007 Oxfordshire Bioscience Network (press release),Fourth-quarter sales of Fabrazyme® (agalsidase beta) for Fabry disease were $96 million, up 18 percent from $82 million in the same quarter a year ago. Genzyme Sales Rise in 4Q - Jan 9, 2007 BusinessWeekGenzyme reported sales of Fabrazyme at $96 million, up 18 percent from $82 million last year. Fabrazyme is the only drug on the market to treat Fabry Genzyme's revenue up 17 percent in quarter - Jan 9, 2007 Boston Globe,Fourth quarter sales of Fabrazyme for Fabry disease were $96 million, up 18 percent from $82 million last year. The company said full-year sales of the drug Genzyme expects 2007 profit to rise on drug sales - Jan 9, 2007 ReutersFourth-quarter sales of Fabrazyme, the company's drug to treat Fabry disease, which causes blood fats to build up in blood vessels, rose 18 percent to $96 Genzyme reports 17% jump in fourth-quarter revenue - Jan 9, 2007 MarketWatchFabrazyme drug sales were up 18% from last year to $96 million. The biotech bellwether went on to forecast that 2007 revenue will come in between $3.6 : |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines mongabay.com
COPYRIGHT 2007 MONGABAY.COM |